Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler

This study is currently recruiting participants.

Verified by AstraZeneca, August 2007

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00524641

Purpose

To investigate the change in patient's asthma symptom control using ACQ scores after 4 to 6 weeks of Symbicort Turbuhaler (budesonide/ formoterol) in SMART approach.

Condition
Asthma

MedlinePlus related topics: Asthma

Drug Information available for: Formoterol Arformoterol Arformoterol Tartrate Formoterol fumarate Budesonide Symbicort

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Cross-Sectional, Convenience Sample, Prospective Study
Official Title:	A Patient Follow-up Program to Assess Asthma Control in Patients Using Symbicort® as Maintenance and Relief Therapy in a Single Inhaler (Symbicort® SMART: Budesonide/Formoterol 160/4.5 Mcg, 1 or 2 Inhalations x 2 Times Plus Additional Inhalations as Needed)

Further study details as provided by AstraZeneca:

Estimated Enrollment:	1425
Study Start Date:	July 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Asthma patients from both sexes, age 18 or older
Have already been on Symbicort SMART treatment
Willing to give written informed consents to participate in the program.

Exclusion Criteria:

Patients who are not willing to give written informed consent
Patients in emergency care for asthma at ICUs or COPD patients are excluded from the program.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00524641

Contacts

Contact: AstraZeneca Vietnam Clinical Study, Information

+84-8278088

ngocthieu.nguyen@astrazeneca.com

Locations

Vietnam
Research Site	Recruiting
Ho Chi Minh City, Vietnam
Research Site	Recruiting
Hanoi, Vietnam

Sponsors and Collaborators

AstraZeneca

Investigators

Study Chair:	Dinh Ngoc SY, MD	TB and Lung Disease Hospital, Hanoi
Study Chair:	Tran Van Ngoc, MD, PhD	Cho Ray Hospital
Study Chair:	Nguyen Hong Duc	Pharm Ngoc Thach Hospital
Study Chair:	Do Van Dung, MD, PhD	Ho Chi Minh City Univ of Medicine and Pharmacist

More Information

Related Info This link exits the ClinicalTrials.gov site

Study ID Numbers:	NIS-R84-AST-2007/3
Study First Received:	August 30, 2007
Last Updated:	August 31, 2007
ClinicalTrials.gov Identifier:	NCT00524641
Health Authority:	Vietnam: Ho Chi Minh City Health Service

Keywords provided by AstraZeneca:

Asthma
Symbicort
NIS

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Symbicort
Respiratory Tract Diseases
Lung Diseases

Budesonide
Hypersensitivity, Immediate
Formoterol
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Respiratory System Agents
Immune System Diseases
Bronchial Diseases

Therapeutic Uses
Anti-Asthmatic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009